Saturday , November 25 2017
Home / Letter From The Editor / March 5, 2016

March 5, 2016

dave

Ever since GLP-1 analogs have been available, there have been a lot of worries about cardiovascular problems. Part of this was brought on by Dr. Steven Nissen’s full frontal attack on the TZD’s (later proven to not be true). His angry commentary on the cardiovascular risks of diabetes drugs put a damper on a lot of physicians using the GLP-1 analogs, and billions of dollars have been spent to study the effect of this class on cardiovascular health.

This week the results of the LEADER Trial were published: a 9100 patient, 5-year study of the use of  liraglutide (a once-daily GLP-1 analog) and cardiovascular risk. Click here to see the results, and then you can decide how best to treat your patients.

Announcements:

Diabetes Summit 2016

DIC Publisher Steve Freed will be attending the GTCbio 2016 Diabetes Summit, to be held April 25-27, 2016 in Boston, MA.  This unique event encompasses the drug discovery and partnering aspects of diabetes in two individual conferences that take place concurrently. Click here for more information.

Free CME Courses
Our web site CME resource is back online! Be sure to check out the new CME courses posted there. Courses are currently available on topics including: Advances in the Medical & Surgical Management of Obesity; Diabetic Retinopathy; Strategies to Improve Prevention and Treatment of Diabetes; and more!

dLifeTV.com: Sunday, March 6, 7PM ET

From dLife.com: “dLife demystifies different types of insulin, from animal to analog. Plus, an extreme diabetes makeover, and a slow cooker favorite from the dLife kitchen.” Sundays live online at dLifeTV.com at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at dLifeTV.com.

*****************************

We can make a difference!

*****************************

Dave Joffe, Editor-in-chief